23价肺炎球菌多糖疫苗预防不良心血管事件:一项随机临床试验
该双盲安慰剂对照随机试验在澳大利亚6个中心纳入4725名55-60岁、有至少2项心血管危险因素但无既往心血管事件的社区成人,随机接种PPV23或安慰剂,平均随访7年。探索性终点全因死亡、全因住院和心血管相关住院操作亦无显著差异,但事件率低于预期导致把握度不足。
要点
- PPV23未显著降低主要心血管复合终点风险。
- 全因死亡、住院等探索性终点亦无显著差异。
- 事件率低于预期,研究把握度不足,结论需谨慎解读。
核心结论
- PPV23未降低致死性和非致死性急性冠脉综合征及缺血性卒中的发生率,但研究把握度不足。
研究设计与样本
- 双盲、安慰剂对照、平行组随机临床试验,在澳大利亚6个中心开展。
- 纳入4725名55-60岁、有至少2项心血管危险因素(肥胖、高血压或高胆固醇血症)但无既往心血管事件或早期肺炎球菌疫苗接种指征的社区成人。
- 参与者随机接受23价肺炎球菌多糖疫苗(PPV23)或安慰剂(生理盐水),平均随访7年。
- 主要终点通过电子病历(急诊、住院和死亡数据)使用ICD-10-AM编码确定。
- 数据分析采用竞争风险比例风险回归模型,按性别和中心分层。
主要发现
- 探索性终点全因死亡、全因住院和心血管相关住院操作均无显著差异。
- 事件率低于预期,导致研究把握度不足。
临床怎么用
- 基于本试验结果,不应以预防心血管事件为目的对无心血管疾病的中老年人群接种PPV23。
- 肺炎球菌疫苗接种仍应遵循现有肺炎球菌疾病预防指征。
局限性
- 事件率低于预期,研究把握度不足,可能掩盖潜在的小效应。
- 研究人群为55-60岁、有心血管危险因素但无既往心血管事件者,结论外推受限。
- 平均随访7年,可能不足以观察晚期获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Animal studies and meta-analysis of human observational data suggest that pneumococcal polysaccharide vaccination (PPV) could be protective against atherosclerosis; however, to the authors' knowledge, no randomized clinical trial has been conducted. OBJECTIVE: To determine whether pneumococcal vaccination (Pneumovax [Merck Sharp & Dohme Corp]) decreases the composite primary outcome of fatal and nonfatal acute coronary syndrome and ischemic stroke in people at increased risk, with an average follow-up of 7 years after immunization. DESIGN, SETTING, AND PARTICIPANTS: This was a double-blind, placebo-controlled, parallel-arm randomized clinical trial conducted at 6 centers across Australia. Participants were community-dwelling adults 55 to 60 years of age at baseline in 2016 to 2017, with at least 2 risk factors (obesity, hypertension, or hypercholesterolemia) for cardiovascular disease (CVD) but no prior CVD event or indication for early pneumococcal vaccination. Data were analyzed from February 2023 to December 2024 using competing risk proportional hazards regression models, stratified by sex and center. INTERVENTIONS: Participants received either 23-valent PPV (PPV23) or placebo (saline). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of fatal and nonfatal myocardial infarction or ischemic stroke, ascertained via electronic medical records from emergency department, admitted patient, and mortality data collections using International Statistical Classification of Diseases, Tenth Revision, Australian Modification (ICD-10-AM) codes. RESULTS: A total of 4725 participants (mean [SD] age, 58.0 [1.7] years; 2433 male [52%]) were included in this study. There was no significant difference in the primary outcome (58 of 2366 events in the active PPV23 group compared with 64 of 2357 events in the control group, hazard ratio, 0.90; 95% CI, 0.63-1.28; P = .57). Similarly, no significant differences occurred in the exploratory outcomes of all-cause mortality, all-cause hospital presentations, and CVD-related hospital procedures. These results are tempered by the lower than expected event rate leading to low power. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial found that PPV23 did not reduce the rates of fatal and nonfatal acute coronary syndrome and ischemic stroke, although the study was underpowered. TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12615000536561.
引用
- Hure, Peel, D'Este, et al. Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40960793. doi:10.1001/jamacardio.2025.3043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。